In the current study, we administered the loaded nanovectors to a syngeneic model of murine glioma, both intravenously and via a nose-to-brain route, to evaluate its potential in high-grade glioma, which expresses high amounts of the ferritin transporter, TfR1 [44]. The gene discussed is TFRC; the disease is central nervous system cancer.